Vita 34 AG

V3V

Equity

ISIN DE000A0BL849 / Valor 2333201

Xetra (2024-09-18)

EUR 4.40-3.93%

Vita 34 AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Vita 34 AG is a full-service provider in the field of cell banking and stem cell banking, offering services from removal and processing to preservation and delivery. With approximately 100 employees, the company specializes in storing stem cells for medical purposes, providing a crucial service for individuals looking to safeguard their health and well-being. Vita 34 AG's expertise in this niche area of healthcare positions them as a key player in the industry, catering to the growing demand for personalized medical solutions.

Summarized from source with an LLMView SourceSector: Healthcare

EBITDA Performance

Vita 34 AG reported an EBITDA of 5.6 million euros for the fiscal year 2023, significantly surpassing the preliminary estimate of 4.0 million euros announced in January. This improvement is attributed to positive effects from the harmonization of accounting under IFRS 15 and a more favorable assessment of risks related to hyperinflation in Turkey.

Revenue Growth

For the year 2023, Vita 34 AG achieved revenue of 77.1 million euros, marking an 11.8% increase compared to the previous year's revenue of 68.9 million euros. This growth reflects the company's strong market position and successful business strategies.

Future Outlook

Looking ahead, Vita 34 AG's management forecasts further improvements in revenue and earnings for 2024. The company projects revenue to be in the range of 81 to 88 million euros, with an expected EBITDA between 6.5 and 8.0 million euros.

Final Financial Report

Vita 34 AG plans to release its complete financial report for the fiscal year 2023 on April 30, 2024. This report will provide detailed insights into the company's financial performance and strategic initiatives.

Company Profile

Founded in 1997 in Leipzig, Vita 34 AG is Europe's leading cell bank and the third largest globally. The company specializes in the cryopreservation of stem cells from umbilical cord blood and tissue, serving customers in around 50 countries with approximately one million units of stored biological material.

Summarized from source with an LLMView Source

Key figures

-9.47%1Y

-72.4%3Y

-63.0%5Y

Performance

45.4%1Y

45.2%3Y

45.6%5Y

Volatility